top of page

New Strategies in Treating Respiratory Failure: NIV and HFNO as complementary therapies


Nicholas S. Hill, MD

Chief, Pulmonary & Critical Care and Sleep Division Pulmonary, 

Critical Care and Sleep Division
Tufts Medical Center

Boston, MA


F. Javier Belda, MD, PhD

Professor of Anaesthesiology and Critical Care.

Department of Surgery. Faculty of Medicine and Odontology.

University of Valencia, Spain


Thomas Piraino, RRT, FCSRT, FAARC

Clinical Specialist  

Centre of Excellence in Mechanical Ventilation

St. Michael’s Hospital 

Toronto, Ontario



Noninvasive ventilation (NIV) benefits have become increasingly recognized, in particular, NIV has proven effective for hypercapnic respiratory failure. High-flow nasal cannula (HFNO) has shown promise in treating hypoxic respiratory failure. This presentation will discuss how HFNO with NIV enables a complementary approach for weaning efficiency. In light of the current pandemic, this presentation will also discuss the use of HFNC and NIV therapy in COVID-19 patients. Following the lecture with be an interactive panel discussion with three experts in HFNO and NIV therapies.


Learning Objectives:

Upon completion of this activity, the participant will be able to:

1. Discuss indications for NIV and HFNO

2. Discuss the use of HFNO and NIV therapy in COVID-19 patients

3. Demonstrate how HFNO and NIV can work in complementary fashion

bottom of page